OncoAlert (@oncoalert) 's Twitter Profile
OncoAlert

@oncoalert

🌐 Worldwide Network of Oncology Professionals & Patient Advocates with the common goal of ending cancer, we are Oncology360 degrees 🌎 We are #OncoAlert 🚨

ID: 1109128247789395968

linkhttp://www.OncoAlert360.com calendar_today22-03-2019 16:22:35

103,103K Tweet

38,38K Takipçi

157 Takip Edilen

OncoAlert (@oncoalert) 's Twitter Profile Photo
OncoAlert
@oncoalert

4 months ago

NEWS FROM INDUSTRY🚨 Source AstraZeneca DESTINY-Breast11 Update The DESTINY-Breast11 Phase III trial sees trastuzumab deruxtecan followed by paclitaxel, trastuzumab, and pertuzumab (THP) improved pathologic complete response rates compared to the standard neoadjuvant regimen of

NEWS FROM INDUSTRY🚨 Source AstraZeneca DESTINY-Breast11 Update The DESTINY-Breast11 Phase III trial sees trastuzumab deruxtecan followed by paclitaxel, trastuzumab, and pertuzumab (THP) improved pathologic complete response rates compared to the standard neoadjuvant regimen of